No Data
Pharmaron (03759) plans to acquire 80 million yuan of unsubscribed but yet-to-be paid AstraZeneca fund shares held by Jiangsu Yuyue Medical Equipment & Supply.
Pharmaron (03759) has announced to fully leverage its industry-leading position in medical and health fields as well as its globalized industry chain.
Jiangsu Yuyue Medical Equipment & Supply (002223.SZ) intends to transfer its shares of industrial investment fund to Pharmaron.
On August 16th, Gelunhui reported that Jiangsu Yuyue Medical Equipment & Supply Co., Ltd. (002223.SZ) announced that the company signed a "Transfer Agreement of Property Interests in Wuxi AstraZeneca CITIC Entrepreneurial Investment Partnership Enterprise (Limited Partnership)" with Pharmaron (Beijing) New Drug Technology Co., Ltd. (referred to as "Pharmaron"), CITIC Private Equity Funds Management Co., Ltd. (referred to as "CITIC Private Equity"), and AstraZeneca Business Consulting (Wuxi) Co., Ltd. (referred to as "AstraZeneca") on August 16, 2024. The company transferred its subscribed capital contribution to the partnership enterprise of RMB 80 million to Pharmaron at a price of RMB 0.
Pharmaron (03759.HK) held a board of directors meeting on August 27 to review and approve its mid-term performance.
Pharmaron (03759.HK) announced on August 14th that the board of directors meeting will be held on Tuesday, August 27th, 2024 to review and approve the interim performance of the company and its subsidiaries for the six months ended June 30th, 2024, which includes its release.
PHARMARON: NOTICE OF BOARD MEETING
Hong Kong stocks fluctuated | CXO concept stocks fell in early trading, Geopolitical game has yet to land, CXO industry prosperity still fluctuates.
CXO concept stocks fell in early trading. As of press time, Tigermed (03347) fell 5.89% to HKD 31.9; Pharmaron (03759) fell 4.04% to HKD 9.02; Wuxi AppTec (02359) fell 3.75% to HKD 33.35; and Frontage (01521) fell 1.35% to HKD 0.73.
Pharmaron (03759.HK) has completed industrial and commercial registration changes and issued a new business license.
Pharmaron (03759.HK) announced on August 12th that Pharmaron (Peking) New Drug Technology Co., Ltd. (hereinafter referred to as the 'Company') held the 2023 annual shareholders meeting, the 2024 first A-share category shareholders meeting, and the 2024 first H-share category shareholders meeting on June 6, 2024 to approve the Proposal 1 on increasing registered capital and revising the Company's Articles of Association, and Proposal 2 on increasing registered capital and revising the Company's Articles of Association. Recently, the company has completed the relevant industrial and commercial registration procedures and obtained the Beijing economic technology ...
No Data
